Market Research Blog – Page 14518 – New Product Development

Osteoarthritis Gene Therapy Market is expected to grow at a CAGR of 8.7% During the Time Period Of 2022-2031

According to the latest research by Future Market Insights, the osteoarthritis gene therapy market is expected to grow at a CAGR of 8.7%. The demand outlook is anticipated to develop steadfast during the forecast period.

The providers of this therapy are expected to go through a high demand phase that would offer them various opportunities for progress.

What are the major drivers of the Osteoarthritis Gene Therapy demand?

Osteoarthritis (OA) is one of the leading cause of disability in the western world. According to the Osteoarthritis Foundation International, the prevalence of OA is approximately 500 million people, globally.

Get the whole details from Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-14033

The disease is characterized by being incurable, incurring immense treatment cost but responding very poorly to the treatment. The fact that OA is a debilitating disease and gene therapy provides a hope for treatment and pain reduction, there is a very high demand for this therapy, globally. This is one of the major driver for this market.

The presence of a large number of geriatric and target patients, as well as improved healthcare infrastructure in several countries in the Asia-Pacific region, is expected to open up market opportunities during the forecast period.

CRISPR/Cas9 system: The latest technique in gene therapy

A novel approach to gene editing using the CRISPR / Ca9 system bypasses disease-causing mutations in a gene, providing treatment for single-gene-related genetic diseases such as cystic fibrosis, certain types of sickle cell anemia and other rare diseases.

The CRISPR / Ca9 system has created promising new therapies for genes that can target and correct disease-causing mutations in a gene. In this process, Cas9 – a bacterial protein – cuts DNA at a specific location where it can edit, trim the genetic sequence, or insert a new sequence before repairing the DNA.

U.S. and Canada: Osteoarthritis Gene Therapy demand outlook

The Osteoarthritis gene therapy market in the U.S. and Canada regions is expected to be slightly affected due to the COVID-19 pandemic. The demand is supposed to show slight growth due to the government investments in various R&D activities in cell based research.

Since the gene therapy can be personalized for every patient’s need, this is anticipated to drive the demand outlook in these regions.

Europe: Osteoarthritis Gene Therapy demand outlook

The European region dominated osteoarthritis gene therapy market during the year 2020. This can be attributed to various reasons that contribute to the demand of this therapy such as rising prevalence of osteoarthritis cases in the region, increased geriatric population due to increased access to advanced medical care and rising obesity rates in various countries of Europe.

Who are the key players in the Osteoarthritis Gene Therapy market?

The key players in osteoarthritis gene therapy demand outlook are

Flexion
GeneQuine
Novartis
Smith & Nephew
Genascence
Kolon TissueGene
Sanofi
Paraxel
Medipost co ltd
and Mundipharma.

On 19^th November 2018, Mundipharma signed a multi-year agreement with Kolon Life Sciences, where they secured the exclusive rights for Invossa osteoarthritis therapy in Japan. This collaboration was intended to ensure that all the patients suffering from osteoarthritis in Japan had access to latest breakthrough treatments like Invossa.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Osteoarthritis Gene Therapy Market Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size recent industry trends
Key Competition landscape
Strategies for key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Note: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Download the TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-14033

Key Segments:

By Site of Injection:

Synovium
Cartilage

By Vectors

Non-viral
Retrovirus
Lentivirus
Adenovirus
Adeno-associated virus (AAV)
HSV

By End-User

Hospitals and clinics
Orthopedic Centers
Assisted living Facilities
Nursing Homes
Ambulatory Surgical Centers
Others

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Western Blotting Market is anticipated to ascend at nearly 6.0% CAGR through 2021-2031

According to Future Market Insights (FMI), the global western blotting market is expected to expand at close to 6.0% CAGR during the forecast period of 2021 to 2031.

Western blotting, being the gold standard and confirmatory test for HIV diagnosis, is gaining traction around the world. As the increase in applications in diverse fields such as agriculture, diagnostics, life science research, to name a few, tends to persist, manufacturers operating in this industry are getting more inclined to bring in wider variety of products. The updated edition of Future Market Insights’ study tracks growth in over 20+ markets, covering the regulatory framework as well as strategies of leading players.

Rise in prevalence of AIDS coupled with the increase in research & development (R&D) activities in proteomics field continues to drive adoption of western blotting industry. According to the report titled “Global HIV & AIDS Statistics- 2020 Fact Sheet” published by the UNAIDS Organization, 38 million people globally were living with HIV in 2019, while 75.7 million people have become infected with HIV since the start of the epidemic (end 2019). These data represent the unlimited opportunities awaiting for suppliers and manufacturers in western blotting industry.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1050

Key Takeaways from Study

Electrophoresis blotting systems remain the preferred product type
Surge in demand from pharmaceutical and biotechnology sectors to fuel sales of western blotting products
Growing application in scientific research to favor stakeholders in western blotting industry
US will remain the most lucrative market for western blotting globally
Germany to maintain the lead in the world’s second largest western blotting market Europe
Asia-Pacific to witness the fastest growth rate, while being led by China, India, and Japan
The United Kingdom, France, Canada, Italy, and a few other countries remain lucrative for western blotting product manufactures

Rise in Awareness Regarding Early Diagnosis of HIV Aiding Growth

Western blotting is highly efficient in separating the blood proteins and detecting the specific proteins called HIV antibodies in diagnosis of HIV or AIDS. According to a report published by the HIV Government on 25^th November, 2020, about 81% of people with HIV worldwide have been tested and know their HIV status. As per the report, an estimated 1.7 million individuals worldwide acquired HIV in 2019, marking a 23% decline in new HIV infections since 2010. While these figures represent the growing awareness, it also indicates the increase in requirement for western blotting products since the past decade.

As stated in the global statistics report published by the HIV Government, AIDS-related deaths have been reduced by 60% since the peak in 2014, while in 2019, around 690,000 people died from AIDS-related illness worldwide, compared to 1.1 million in 2010. As per the report, the global commitment to stop new HIV infections and ensuring that everyone has access to HIV diagnosis & treatment is bound to yield positive results. This also implies the surge in demand for western blotting products in the coming years.

Who is Winning in this Space?

The global western blotting market offers remains fiercely competitive. In order to consolidate their position, key market players are launching wide variety of western blotting solutions.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1050

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Automated Breast Ultrasound System Market is slated to grow at approximately 10% CAGR over the forthcoming decade

Rising prevalence of breast cancer across the globe and increasing government initiatives undertaken to encourage breast cancer awareness have significantly fuelled the demand for automated breast ultrasound system, according to ESOMAR-certified Future Market Insights’ (FMI) latest research report. As per the study, the global automated breast ultrasound system market is slated to grow at approximately 10% CAGR over the forthcoming decade.

Key manufacturers are actively focusing on developing faster, accurate and minimal invasive ultrasound breast imaging system. According to report published in National Library of Medicine, integration of mammography with automated breast ultrasound system increased the sensitivity of the system to 99.1%.

The combination drastically improves cancer detection rate among dense breasted women and reduces the interpretation time. Prominent manufacturer GE Healthcare launched a new automated breast ultrasound system named “Invenia” in U.S in October 2018. The main function of the system is to identify the presence of mammographically occult cancer especially in women with dense tissues.

With various other developments on cards, the automated breast ultrasound system market is expected to showcase impressive growth between 2021 and 2031.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-606

Key Takeaways from FMI’s Automated Breast Ultrasound Systems Market Study

Increasing government investment to promote breast cancer awareness among women will bolster demand across the U.S.
The U.K is expected to experience noteworthy growth as governments and private organizations aim at curbing high mortality rate due to breast cancer.
Presence of modern healthcare infrastructure will increase automated breast ultrasound system adoption across Germany
Saudi Arabia will offer lucrative opportunities owing to rapid urbanization and emergence of advance diagnostics centers.
India is expected to exhibit increasing demand owing to increase in per capita income and to growing incidence of breast cancer among women.
Hospitals are expected to lead the market driven by faster accessibility modern tool and availability of skilled professionals.

Competitive Landscape

GE Electric Co., Siemens A.G., Hitachi Ltd., SonoCiné Inc., Koninklijke are some prominent players operating in the automated breast ultrasound system market. They are focusing on improving the accuracy of automated breast ultrasound system for faster assessment of cancer screening in addition to getting government approval for their products.

For instance, Hitachi being the global leader in smart life & eco-friendly systems launched its latest automated breast ultrasound system “SOFIA” capable of scanning and acquiring image of the complete breast.

Koninklijke launched Philips EPIQ and Affiniti ultrasound systems as a part of its automated breast ultrasound system product range. Philips EPIQ is laced with an integrated eL18-4 transducer and employs anatomical intelligence for accurate imaging of the breast with high tissue density.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-606

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Halal Nutraceutical & Vaccines Market is expected to reach US$ 116.38 Billion by 2031

ESOMAR-certified consulting firm Future Market Insights’ report, projects a steady growth of global halal nutraceutical & vaccines market. The report has forecast the market to reach a valuation of US$ 116381.3 Mn over the forecast period of 2021 and 2031.

Growing demand for halal dietary supplements from Muslim dominant countries is accelerating the demand of halal nutraceutical & vaccines across the globe.

Key players are investing heavily in order to adhere to the regulations of halal products to cater the demand. Initiatives undertaken and increased funding for the promotion of halal dietary supplements across Malaysia, UAE, Singapore and China will bolster the growth.

Development of halal products for vegetarian customers with the increasing prevalence of lifestyle disorders such as diabetes, obesity and others are propelling the demand for halal dietary supplements.

As per the FMI’s analysis, due to the high demand from the GCC countries, Indonesia and Malaysia for dietary supplements & other products, the market witnessed steady growth at 6.50% CAGR during 2016-2020.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-2703

However, high cost of production in compliance to the regulation of halal certification will impede the market growth. Less production and demand from the U.S, the U.K and other western countries might hamper the demand.

Key Takeaways from FMI’s Halal nutraceutical & vaccines Market Study

By distribution channel, hospital pharmacies segment will remain highly sought-after for halal nutraceutical & vaccine sales.
In terms of application type, general wellbeing will retain its dominance, while immune & digestive health will account for second largest application
Halal dietary supplements will dominate the halal nutraceutical & vaccines market in terms of product over the forecast period
Indonesia and Switzerland will emerge as the leading market across Asia Pacific excluding Japan backed by the high demand of halal dietary supplements
UAE will emerge as the most lucrative market registering fastest growth in terms of value over the forecast period
Malaysia is anticipated to lead the Asia’s Halal nutraceutical & vaccines market, exhibiting the growth at 18.3% CAGR

Competitive Landscape

Prominent halal nutraceutical & vaccines market players profiled by Future Market Insights include Chemical Company of Malaysia Berhad, Abbott Laboratories, Nestle, Amway, Herbalife International of America Inc., AJ Biologics SDN BHD, Agropur Inc., PT Kalbe Farma TBK, Kotra Pharma SDN BHD, and Noor Vitamins among others.

Abbott Laboratories and Herbalife International of America, Inc. are two leading companies dominating the global halal nutraceuticals & vaccines market.

While Abbott Laboratories is expected to focus on producing halal nutraceutical & vaccines for infants, women and specific therapeutic nutrition, Herbalife is emphasizing its business measures more towards consumer awareness through promotional campaigns.

Multinational food & beverage companies like Nestlé S.A. and Amway are also increasing their presence in the global halal nutraceutical & vaccines market to gain competitive edge.

Chemical Company of Malaysia Berhad, AJ Biologics Sdn Bhd., Agropur, Inc., and Kotra Pharma (M) Sdn Bhd, are also recognized as the leading companies in the global halal nutraceutical & vaccines market.

Increasing initiatives for the certification of halal products and demand from Middle East countries are widening the growth opportunities for the leading players. Increasing demand for halal dietary supplements across Malaysia and Indonesia will broaden the future expansion prospects for the market players.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2703

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Injectable Drug Delivery Market Expanding at a healthy 8.9% CAGR, the market size is projected to total US$ 69.13 Billion by 2028

According to the latest report published by Future Market Insights, titled ‘Global Injectable Drug Delivery Market: Global Industry Analysis 2013–2021 and Opportunity Assessment, 2022–2028’, the Global injectable drug delivery market is expected to expand at a CAGR of 10.9% over the forecast period, 2022–2028.

FMI estimates that the global market for injectable drug delivery was valued at US$ 10,400.0 Mn in 2021 and is expected to expand at CAGR of 10.9% over 2022–2028, to reach US$ 32,136.9 Mn by 2028 end. Based on product type, the needle-free injectable drug delivery segment dominated the global injectable drug delivery market in 2017. Moreover, the subtype, prefilled of needle-free injectors segment is expected to have a dominant share of the needle-free type of injectable drug delivery market due to its ease of application. North America is expected to maintain its dominance in the global injectable drug delivery market due to the presence of a large number of manufacturers of injectable drug delivery devices, mostly operating from the U.S.

Increase in prevalence of chronic diseases such as diabetes, cancer and rheumatoid arthritis along with other factors such as need for patient-controlled drug release and increased risk of needle stick injuries are the prominent factors expected to drive the growth of the injectable drug delivery market. Technological advancements have resulted in better product offerings in the injectable drug delivery market. However, some factors such as strict regulatory framework and premium pricing of products are expected to hinder the growth of the injectable drug delivery market. The key trend of the injectable drug delivery market is the increasing demand for point-of-care devices. Injectable drug delivery devices are easy to self-administer and do not require a healthcare professional for administration, which as a result skips the need of hospital visits and relatively lowers the healthcare spending for an individual.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-393

The global injectable drug delivery market has been segmented on the basis of product type, usage, end users and regions. The disposable injectable drug delivery segment is expected to be the most attractive usage segment. Among the three end users, the hospital pharmacies is expected to be the dominant segment due to benefits such as favourable reimbursement policies in most of the countries across the globe.

In terms of value, the global injectable drug delivery market is expected to expand at 10.9% CAGR over the forecast period. With nearly 32% market share, North America was a dominant regional market for injectable drug delivery in 2017, due to growing number of manufacturers in the region and early adoption of new technologies. Western Europe is expected to be the second large market in injectable drug delivery, with Germany, the U.K. and France occupying major shares. APEJ is expected to be third large market for injectable drug delivery, due to requirement of low capital for manufacturing injectable drug delivery.

Key Research Findings

Increase in demand for point-of-care devices and reduced reliance on healthcare facilities are driving the growth of the global injectable drug delivery market
North America will be the dominant regional market for injectable drug delivery devices due to early adoption of advanced technologies
Most of the major players operate from the U.S., which makes the U.S. the leading market for injectable drug delivery devices in North America
In Europe, a large number of diabetes patients are switching towards needle-free injectable drug delivery devices from conventional injections since it is a painless process and reduces the risk of needle stick injuries
Disposable injectors are the most commonly available type of injectors since they are user friendly and do not require special skills for administration
Prefilled needle-free injectors are the most preferred type of injectors since they are much easier to administer than the fillable type
Price control for most of the injectable drug delivery devices is fierce. For instance, Mylan was pressurised to launch the generic version of the EpiPen to reduce the price of the product in the market. However, this has declined the revenue of the company.
In developed regions, such as North America and Europe, hospitals are the dominant distribution channel due in injectable drug delivery due to the reimbursement policies
The growing competition in the emerging market and the rising demand for injectable drug delivery are the future opportunities for the growth and expansion of the injectable drug delivery market.

Examples of some of the key players identified in the global injectable drug delivery market include Amgen Inc., Medtronic PLC, West Pharmaceutical Services, Yepsomed, Becton, and Dickinson And Company, Antares Pharma, Mylan, SHL Group, Endo International PLC, Crossject, and Consort Medical (Bespak), among others.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-393

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Companion Animal Vaccines Market is expected to grow at a CAGR of 6.9% over the forecast period 2022-2028

Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the sales of companion animal vaccines in global market. Surpassing the revenues worth US$ 2.5 Bn in 2021, global companion animal vaccines market is projected to exhibit a robust CAGR during 2022 – 2029. Measurable rise in the zoonotic disease prevalence will remain a key factor fueling the demand for companion animal vaccines and drugs.

FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines. For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1427

Key Takeaways – Companion Animal Vaccines Market Study

Attenuated live vaccines currently account for more than a third of total market value, and will continue to witness a healthy CAGR through 2029. This demand growth is attributed to their improved effectivity and enhanced long-term preventive action.
North America is witnessing lucrative market growth compared to other regions attributed to increase in the adoption rate of companion animals, increase in veterinary healthcare expenditure, and increasing awareness about pet health.
Veterinary animal hospitals and clinics offering better service support for animal care are expected to have significant market share during the forecast period
As large number of people are in close contact with canine animals as a preference for companion animal, demand will be prominent among canine species.

Increasing R&D Investments to Widen Market Growth Prospects

Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market. These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases. Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.

For instance, in August 2021, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics. Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines. For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1427

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Negative Pressure Wound Therapy (NPWT) Market Expanding at a healthy 6.9% CAGR, the market size is projected to top US$ 3.4 Billion in 2026

Effectiveness of negative pressure wound therapy (NPWT) in treating acute and chronic wounds is a key factor driving its adoption across hospitals, clinics, and homecare settings. The use of NPWT devices in managing closed incisions, where the risk of wound breakdown is higher, is also fuelling the growth of the negative pressure wound therapy market, especially in North America and Western Europe.

Development of safe and highly-effective negative pressure wound therapy devices has helped address concerns related to potential risks, leading to greater adoption across end-use sectors. Decline in the number of adverse reaction and product recalls has led to increased confidence on the safe use of NWPT.

FMI-a well-established name in the market research domain – forecasts that, the NPWT market will experience a major upturn post 2025, reaching a valuation of US$ 3.2 Bn by 2029.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-810

Key Takeaways of NPWT Market Study

Single-use disposable negative pressure wound therapy devices, under product, are expected to exhibit a CAGR of 8% during the forecast period.
The U.S. is anticipated to dominate the global negative pressure wound therapy market and account for over 86% share of the North America NPWT market.
Hospitals and home care settings segments are expected to dominate the negative pressure wound therapy market during the forecast period, owing to significant adoption of NPWT systems.
Companies are focusing on collaborating with established research centres and other manufacturers to develop products complaint with regulations across the globe that can help in the treatment of chronic disorders.

Manufacturer of NPWT Devices Focusing on Launch of Portable and Disposable Devices

Over the last few years, leading manufacturer have been focusing on introducing portable and disposable NPWT devices, targeting a range of consumers, including hospitals, homecare settings, etc. Presently, a majority of NPWT devices are used in the U.S. and Europe. However, the demand for portable and disposable NPWT devices is gaining traction in APAC, Eastern Europe, and Latin America.

There has been growing interest in using portable and disposable NPWT devices on closed incisions after a surgical procedure in order to inhibit potential surgical site infections (SSIs) and other wound complications in high-risk patients.

Examples of some disposable NPWT devices from top players include the V.A.C.Via Therapy System, Prevena Incision Management System (Acelity), PICO (Smith and Nephew PLC.), AVELLE Negative Pressure Wound Therapy System (ConvaTec Inc.)

Want more insights?

A new study from Future Market Insights provides detailed information on the evolution of the negative pressure wound therapy market from 2014-2021, and presents demand projections for 2022-2026, on the basis of product (standalone NPWT devices, single-use disposable NPWT devices, portable NPWT devices, and NPWT accessories), and end user (hospitals, clinics, and home care settings), across seven prominent regions.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-810

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Red Light Therapy to Emerge as the Most Widely Preferred Treatment for Multiple Ailments: FMI Study

ESOMAR certified market research company Future Market Insights (FMI) global light therapy market is likely to surpass US$ 1 billion in the short-run, expanding at a moderate CAGR in that time period. Long-term prospects appears largely optimistic, with credible opportunities expected to present themselves with respect to addressing acute depression problems.

As per FMI’s report, growth prospects are likely to emerge across skin and insomnia treatment domains as well. With at least one to three out of ten people experiencing disrupted sleep cycles, patients are seeking effective therapeutic approaches, thereby widening growth prospects. Furthermore, skin ailments contribute to almost 2% of the global burden of disorders.

Manufacturers are primarily emphasizing on introducing portable and lightweight handheld light therapy devices amid the rising demand for flexible therapeutic solutions. For instance, the LightStim For Wrinkles is an award-winning FDA-cleared red light therapy device for skincare, deploying a patented multi-wave technology based on advanced LED technology from NASA. Likewise, the iRestore Laser Hair Growth System for treating androgenic alopecia deploys a 650 mm wavelength red light which is clinically proven to enhance hair growth.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1160

Key Takeaways from FMI’s Light Therapy Market Study

By product, handheld light therapy devices for skin treatment are likely to enjoy highest demand
By light type, demand for red light therapy is expected to reach new heights, characterized by increasing numbers of clinical trials
By end-user, dermatological centers are expected to be primary light therapy treatment centers in forthcoming years
High seasonal affective disorder (SAD) incidence fueling light therapy treatment in the US
UK to attract high investments, characterized by the presence of prominent phototherapy light manufacturers
Germany to generate lucrative growth prospects amid extensive applications across the photodynamic treatment (PDT) segment
Surging dermatological problems to widen natural treatment approaches scope in India, widening prospects for light therapy

Competitive Landscape

Koninklijke Philips N.V., Verilux Inc., Northern Light Technology, Sphere Gadget Technologies, Zepter International, PhotoMedex Inc., Luminette, Klarstein, Lumie and Aura Daylight are some prominent light therapy market players profiled by FMI’s report on the landscape.

Offering new products based on the latest technology is the primary strategy deployed by a majority of the aforementioned market players. For instance, Klarstein offers its 3MC light therapy sunlight SAD disorder lamp for medical purposes. This product is especially suitable for treating for treating seasonal affective disorder by deploying a mid-day simulating spectrum.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1160

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Small-Molecule Injectable Market is expected to reach US$ 112.9 Billion by 2031

The global small-molecule injectable market was valued at US$ 55.8 Bn in 2020. Expanding at a 7.3% CAGR, the market valuation is expected to top US$ 112.9 Bn by 2031, finds ESOMAR-certified consulting firm Future Market Insights (FMI) in a recent market analysis.

The COVID-19 pandemic outbreak has sparked efforts to repurpose already-approved medicines for treatment. Several clinical studies are now being conducted on different antiviral medicines and small-molecule injectables that have been utilized in the past to treat diseases including SARS, MERS, HIV/AIDS, and malaria. For instance, Remdesivir was approved by FDA for the treatment of COVID-19 in hospitalized adult and pediatric patients.

This is expected to fuel sales of small-molecule injectables over the forecast period. Besides this, rising prevalence of chronic illnesses especially cancer and cardiovascular diseases across the globe are anticipated to usher developments in the small-molecule injectables market.

Pharmaceutical companies are aiming at production facility expansions to reduce corporate tax rate (in the U.S.), and to expand their footprints in emerging markets such as India and China, where production cost is low as compared to regions such as Europe and North America.

Recent tax reforms in the U.S., which include reduction of the corporate tax rate, have encouraged various large pharmaceutical and biopharmaceutical companies to invest in production facilities.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-14117

For example, in July 2020, Pfizer announced its plan to invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it made earlier in 2020 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country. These developments are indicative of lucrative growth prospects for small-molecule injectable market players.

Key Takeaways:

By product, the analgesics segment is expected to hold 23.9% of the total small-molecule injectable market in 2021, expanding at 8.0% CAGR.
In terms of applications, demand for small-molecule injectables in the infectious disease segment is expected to hold 31.7% of the total market share in 2021.
By route of administration, the intravenous segment is anticipated to hold 50% of the total market share in 2021.
Sales of small-molecule injectables through hospital pharmacies are projected to account for 67.8% of the total market share in 2021.
The U.S. is anticipated to dominate the North America small-molecule injectables market, holding 92.4% of the market share.
Germany is expected to hold of 21.9% of the Europe small-molecule injectable market share by 2031.
Small-molecule injectable market in China is projected to expand at a 9.0% CAGR over the forecast period.
Demand for small-molecule injectables in India is forecast to grow at an impressive 11.1% CAGR through 2031.
Sales of small-molecule injectables in South Korea and Japan are anticipated to rise at 5.0% and 8.8% respectively.

Competition Landscape

The key market players covered by FMI include Aurobindo Pharma Limited, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., AstraZeneca Plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Baxter International, Fresenius Kabi, Cipla Ltd, Mylan N.V., Sanofi S.A, and Dr. Reddy’s Laboratories Ltd.

Leading manufacturers of small-molecule injectables are focusing on strategic collaborations and partnerships to strengthen product portfolios. Manufacturers are also aiming at production facility expansions through acquisitions and mergers to gain a competitive edge in the market.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-14117

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us:

Peptide therapeutics Market is expected to reach US$ 47 Billion by 2025

Peptide therapeutics are witnessing substantial demand, owing to increasing application in the treatment of various chronic disease such as cancer, cardiovascular diseases, hematologic diseases, and gastro-intestinal diseases.

Rising prevalence of these chronic diseases across the world is further expected to widen the existing patient pool. Therapeutic efficacy of peptide therapeutics is relatively superior as compared to other marketed drugs, resulting in their higher adoption among physicians.

The global peptide therapeutics market was valued at US$ 25.6 Bn in 2021, and is expected to exhibit a healthy CAGR of 11% during the forecast period (2022-2025).

The COVID-19 pandemic has been severely affecting the global economic order, and, in turn, the peptide therapeutics market. Restrictions on traveling, self-quarantines, and social distancing regulations, on a national scale, are resulting in notable drop in business and consumer spending through Q2.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1038

Key Takeaways of Peptide Therapeutics Market Study

In terms revenue generation, among the applications, cancer outperformed other application types, owing to greater prevalence of the disease as well as higher efficacy of peptide therapeutics in cancer treatment.
Various peptide therapeutics are patented, and, in the mid of this decade, a majority of these patents are expected to reach their expiry dates, leading to higher generic competition.
Parenteral route continues to hold the leading revenue share in the peptide therapeutics market, owing to effective drug delivery and higher therapeutic index.

Key Players Focus on Strategic Collaborations and Generic Launches to Widen Regional Presence

Leading players in the peptide therapeutics market, such as AstraZeneca plc, Merck Co. & Inc., and Elli Lily, are concentrating on business expansions through joint ventures and distribution agreements, and are capturing untapped market potential.

Additionally, market incumbents are entering into collaborations in order to expand their regional presence and manufacturing capabilities in the global peptide therapeutics market.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1038

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Contact Us: